Value-Based Reimbursement For Antibiotics Gets Skeptical Reception

Duke Margolis Center floats idea of market entry payments tied to insurance contracts, but insurers and even some sponsors raise concerns, highlighted by question of what constitutes value.

Antibiotic resistant bacteria closeup biofilm

A value-based reimbursement proposal from the Duke University Margolis Center for Health Policy that would incentivize drug companies to prioritize population-based payment contracts with payers was met with skepticism from insurers, government officials and even some sponsors.

Speaking at a Nov. 9 panel on economic incentives for developing antimicrobials, Gregory Daniel, deputy director of the Margolis Center,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet